-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: The small molecule PD13R (magenta) interacts with dopamine D3 (grey) and D2 (purple) receptor low-temperature em structures, as predicted by RhodiumTM
A new study by the Texas Biomedical Research Institute (Texas Biomedical Research Institute, Texas Biomed) and its collaborators has discovered a promising drug candidate that can reduce the uncontrolled, Unstable muscle movement, that is, dyskinesia
This small molecule, called PD13R, reduces dyskinesia by more than 85% in the marmoset animal model of Parkinson's disease
Dyskinesia is a common side effect in patients with Parkinson's disease
"Levodopa is magical.
Designing drugs to treat Parkinson's disease and its side effects is notoriously difficult
In order to identify a compound that only binds to dopamine receptor #3 (D3), Daadi collaborated with the Southwest Research Institute
Daadi and his team at the Texas Biomedical Center explored how the compound targets the D3 receptor in cell culture tests compared to other dopamine receptors
The research team then injected PD13R into the marmoset model of Parkinson's disease
Daadi explained: "We are very excited to see the drug's powerful anti-dyskinesia effect
These animals wear activity monitors and use PD13R.
Daadi and his team plan to continue the safety and efficacy studies required by the U.
Article title
Dopamine D3 receptor ligand inhibits the expression of levodopa-induced dyskinesia in a non-human primate model of Parkinson’s disease
